Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report)'s stock price gapped up prior to trading on Monday . The stock had previously closed at $2.39, but opened at $2.45. Lexicon Pharmaceuticals shares last traded at $2.53, with a volume of 1,065,997 shares traded.
Lexicon Pharmaceuticals Trading Up 7.9 %
The stock has a market capitalization of $631.92 million, a PE ratio of -3.34 and a beta of 1.23. The company has a current ratio of 6.92, a quick ratio of 6.91 and a debt-to-equity ratio of 0.71. The stock has a 50 day moving average price of $1.53 and a 200-day moving average price of $1.43.
Insider Transactions at Lexicon Pharmaceuticals
In other news, CEO Lonnel Coats purchased 90,000 shares of the company's stock in a transaction dated Thursday, November 16th. The shares were purchased at an average cost of $1.05 per share, for a total transaction of $94,500.00. Following the purchase, the chief executive officer now directly owns 914,359 shares in the company, valued at approximately $960,076.95. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 6.80% of the company's stock.
Hedge Funds Weigh In On Lexicon Pharmaceuticals
Institutional investors have recently bought and sold shares of the stock. Raymond James & Associates bought a new position in Lexicon Pharmaceuticals in the 2nd quarter worth $25,000. Bank of Montreal Can bought a new stake in Lexicon Pharmaceuticals during the first quarter valued at about $26,000. Baystate Wealth Management LLC bought a new stake in Lexicon Pharmaceuticals during the second quarter valued at about $28,000. Kestra Advisory Services LLC bought a new stake in Lexicon Pharmaceuticals during the second quarter valued at about $33,000. Finally, ExodusPoint Capital Management LP bought a new stake in Lexicon Pharmaceuticals during the first quarter valued at about $38,000.
About Lexicon Pharmaceuticals
(
Get Free Report)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lexicon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.
While Lexicon Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
